Amine Cationic Lipids and Uses Thereof
AssigneeDicerna Pharmaceuticals, Inc.
InventorsBob Dale Brown, Sujit Kumar Basu, David A. Schwartz, Allister Fraser
Life of this patent
Estimating the term…
Abstract
The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).
Claims28
A compound having the formula:
- or a pharmaceutically acceptable salt thereof,
- wherein
- each R1 and R2 is, independently, optionally substituted C11-24 alkyl, optionally substituted C11-24 alkenyl, optionally substituted C11-24 alkynyl, optionally substituted C11-24 heteroalkyl, optionally substituted C11-24 heteroalkenyl, or optionally substituted C11-24 heteroalkynyl, wherein said R1 and R2 is not substituted with an oxo on the carbon adjacent to >CHNR3R4;
- R3 is H or optionally substituted C1-6 alkyl;
- and
- R4 is unsubstituted C1-6 alkyl that is substituted with —NR4aR4b, substituted C1-6 alkyl that is further substituted with —NR4aR4b, or optionally substituted C3-7 heterocyclyl, wherein each R4a and R4b is, independently, H, C(═NH)NH2, or optionally substituted C1-6 alkyl, or wherein R4a and R4b combine together to form optionally substituted C3-7 heterocyclyl;
- or
- R3 and R4 combine together to form an optionally substituted C3-7 heterocyclyl, or
- R3 and R4 do not combine together and form optionally substituted imidazolyl or optionally substituted benzimidazolyl or optionally substituted succinimidyl;
- wherein one, and only one, primary amine can be present on either R3 or R4 or no primary amine is present on either R3 or R4;
- and wherein neither R3 nor R4 is an optionally substituted amide;
- and wherein when R1 or R2 is saturated C11 alkyl or saturated C15 alkyl, R3 is not H;
- wherein when R1 or R2 is saturated C16 alkyl or saturated C17 alkyl, R1 and R2 is not substituted with hydroxy;
- wherein when R1 or R2 is saturated C17 alkyl, R3 or R4 is not substituted with hydroxy;
- and
- wherein when R1 or R2 is saturated C18 alkyl, R4 is not substituted with optionally substituted imidazolyl.
3-16. (canceled)
19-27. (canceled)
29-30. (canceled)
33-37. (canceled)
39-41. (canceled)
43-44. (canceled)
47-62. (canceled)
A compound, said compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof,
- wherein said compound is, optionally, L-6, L-30, L-48, L-49, or a pharmaceutically acceptable salt thereof.
(canceled)
66-92. (canceled)
95-96. (canceled)
98-99. (canceled)
Dependencies are inferred from the claim text.